Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Stryker is a leading medical technology company with two primary reportable segments: Orthopaedic Implants and MedSurg Equipment. The company operates globally, with domestic sales accounting for 65% of total revenues in Q1 2009.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $1,601.3 million | $1,634.4 million |
| Gross Profit | $1,085.8 million (67.8% margin) | $1,133.9 million (69.4% margin) |
| Operating Income | $379.2 million | $383.7 million |
| Net Earnings | $281.1 million | $290.5 million |
| Diluted EPS | $0.71 | $0.70 |
| Cash from Operations | $272.4 million | $190.8 million |
| Cash & Equivalents | $685.8 million | $701.1 million (Dec 31, 2008) |
| Marketable Securities | $1,559.3 million | $1,494.5 million (Dec 31, 2008) |
| Debt (Current Maturities) | $20.5 million | $20.5 million (Dec 31, 2008) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 2% year-over-year. While unit volume and product mix drove a 4% increase, unfavorable foreign currency exchange rates resulted in a 5% decrease, particularly impacting international sales which fell 7% on a reported basis (though up 7% on a constant currency basis).
- Segment Performance:
- Orthopaedic Implants: Sales remained flat at $973.2 million reported, but grew 6% on a constant currency basis, driven by growth in hips, knees, trauma, and spine products.
- MedSurg Equipment: Sales declined 5% to $628.1 million. This was driven by a 22% drop in patient handling and emergency medical equipment sales, partially offset by growth in surgical equipment.
- Margin Compression: Gross margin decreased from 69.4% to 67.8% due to reduced production absorption, higher compliance costs, and increased freight costs.
- Inventory Build-up: Days sales in inventory increased to 174 days from 155 days at year-end 2008, attributed to sales slowdowns and inventory buildup for compliance initiatives.
- Investment Losses: The company recorded an $8.6 million loss in other income/expense related to the fair value adjustment of Auction-Rate Securities (ARS) Rights, offset by a gain in related trading securities.
Guidance, Outlook, and Risks
Guidance and Outlook
Stryker reduced its 2009 guidance due to weaker demand for MedSurg products and slowing elective procedures for Orthopaedic implants.
- 2009 Diluted EPS: Projected range of $2.90 to $3.10 (2% to 10% increase over 2008 adjusted EPS of $2.83).
- 2009 Net Sales: Projected constant currency increase of 2% to 5%.
- Currency Impact: Anticipated unfavorable impact of 5.5% to 6% on Q2 2009 sales and 3.5% to 4.5% on full-year 2009 sales if exchange rates hold near March 31 levels.
Risks and Contingencies
- Regulatory Actions:
- OP-1 Putty: The FDA Advisory Panel voted not to recommend marketing approval for OP-1 Putty in March 2009. The company is reviewing its strategic plan for the product.
- Grand Jury Investigation: Stryker Biotech is a target of a federal grand jury investigation regarding illegal promotion of OP-1 and Calstrux, sale of misbranded devices, and false FDA reports. Former employees have pled guilty.
- FDA Warning Letters: Received in 2007 and 2008 regarding quality system compliance at facilities in Ireland, New Jersey, and Massachusetts.
- Tax Disputes: The IRS proposed adjustments to 2003-2005 tax returns regarding cost-sharing arrangements with Irish entities. The company intends to vigorously defend these positions, noting a potential material unfavorable impact if the IRS prevails.
- Legal Proceedings: Ongoing investigations by the Department of Justice and HHS regarding consulting contracts with orthopedic surgeons and potential Foreign Corrupt Practices Act violations.
- Liquidity of Investments: The company holds $166.8 million in illiquid Auction-Rate Securities (ARS) due to market failures, though it holds rights to sell them at par to UBS.
Investor Verification Checklist
- OP-1 Strategy: Verify the company's revised strategic plan for OP-1 following the FDA advisory panel's negative vote.
- Regulatory Resolution: Monitor the status of the federal grand jury investigation into Stryker Biotech and the outcome of the IRS tax dispute regarding Irish cost-sharing.
- Inventory Levels: Track the reduction of inventory days (currently 174) to ensure it aligns with sales recovery and does not lead to future write-downs.
- Currency Hedging: Assess the impact of foreign exchange rates on future quarters, given the projected 3.5% to 6% negative impact on sales.
- ARS Liquidity: Confirm the status of the $166.8 million in illiquid Auction-Rate Securities and the valuation of the associated rights agreement.